TU M2-PK在晚期非小细胞肺癌化疗疗效评价中的临床应用价值  

The Clinical Value of TU M2-PK as an Assessment Indicator of Chemotherapeutic Effect in ASCLC

作　　者：彭敏[1] 贾芳[1] 杨迎军[1] 张雪珂[1] 王海洋[1] 李小琳[1] 张海红[1] 

机构地区：[1]保定市第三医院,河北保定071000

出　　处：《临床肺科杂志》2012年第8期1420-1421,共2页Journal of Clinical Pulmonary Medicine

摘　　要：目的评估肿瘤型M2丙酮酸激酶(TU M2-PK)作为一种肿瘤标志物在晚期非小细胞肺癌化疗疗效中的临床价值。方法检测43例晚期非小细胞肺癌化疗前及化疗后1周血浆TU M2-PK进行比较分析。结果晚期非小细胞肺癌化疗后效果:部分缓解(PR)18例,疾病稳定(SD)19例,疾病进展(PD)6例。PR加SD共37例,化疗后较化疗前下降(P<0.05),PD化疗后较化疗前无明显下降(P>0.05)。结论 TU M2-PK测定可作为晚期非小细胞肺癌化疗效果评估的有效指标。Objective To investigate the clinical value of tumor type M2 pyruvate kinase（TU M2-PK） as an assessment indicator of chemotherapeutic effect in advanced non-small cell lung cancer（NSCLC） patients. Methods 43 cases of advanced NSCLC with chemo- therapy were enrolled into this study. The TU M2-PK in the plasma a week before and after chemotherapy were compared and analyzed. Results partial remission （PR） occurred in 18 cases, stable disease （SD） in 19 cases and progressive disease （PD） in 6 cases. The lev- d of TU M2-PK in PR and PD cases （the total was 37 cases） significantly declined after treatment compared with before treatment （P 〈 0.05 ）. There was no obvious decrease in PD cases between pre-treatment and post-treatment （ P 〉 0. 05 ）. Conclusion TU M2-PK can be used as an effective assessment indicator of chemotherapeutic effect in advanced non-small cell lung cancer （NSCLC） patients.

关 键 词：晚期非小细胞肺癌 化疗 肿瘤M2型丙酮酸激酶 

分 类 号：R734.2[医药卫生—肿瘤]